scorecardresearch
Follow Us:
Thursday, June 30, 2022

China gives approval for broader use of Sinovac vaccine

Regulators gave conditional approval for Sinovac Biotech Ltd's shot, Coronvac, on Friday, clearing the way for general use, The National Medical Products Administration announced in a statement Saturday.

By: AP | Taipei |
February 6, 2021 5:37:46 pm
China, Covid-19, Coronavirus, China vaccines, Chinese vaccines, Xi Jingping, Sinovac, Sinopharm, Pfizer, vaccines, vaccine diplomacy, vaccine passports, vaccine failure, coronavirus outbreaks, post vaccination, Mongolia, WHO, Indian Express world news, covid-19 booster shot, variants, virus variants, Delta variant,Pfizer and BioNTech would be able to redesign their shot within six weeks and ship initial batches within 100 days, BioNTech added. BioNTech ADRs gained 14.2% to close at $348 on Friday and Pfizer shares rose 6.1% to end at $54.

Written By Huizhong Wu

China has given broader approval for the domestic-made Sinovac coronavirus vaccine, expanding those who can receive it beyond the high-risk and priority groups already allowed under an emergency clearance.

Regulators gave conditional approval for Sinovac Biotech Ltd’s shot, Coronvac, on Friday, clearing the way for general use, The National Medical Products Administration announced in a statement Saturday.

The Sinovac vaccine has already been sold to at least 10 other countries and is being administered to people in at least five other countries. In China, the shot was given emergency approval last July, allowing people such as medical workers and employees of state-owned firms to receive it.

Best of Express Premium
TN Finance Minister Palanivel Thiaga Rajan: ‘Don’t know of a ...Premium
Efforts to estimate poverty from 2011-21 are commendable, given absence o...Premium
Uddhav Thackeray: The reluctant politician who in the end hung on to chai...Premium
Udaipur killers and Da’wat-e-Islami: the group, its ideology and its growthPremium

The conditional approval means the vaccine can now be given to the general public, though research is still ongoing. The company will be required to submit follow-up data as well as reports of any adverse effects after the vaccine is sold on the market.

It is the second locally made vaccine to be given conditional approval. Beijing authorised the state-owned Sinopharm’s vaccine in December.

Both Sinovac’s shot and Sinopharm’s shot are two-dose inactivated vaccines, relying on traditional technology that makes it easier to transport and store than Pfizer’s vaccines, which requires ultracold storage. That could make a difference for developing countries that have fewer resources.

Sinovac’s vaccine however, has also been subject to intense scrutiny and criticism for lack of transparency. It has announced different efficacy data in different countries across the world. Officials in Turkey, where part of the stage 3 clinical trials were staged, have said the efficacy rate was 91.25 per cent.

But in a much bigger trial in Brazil, officials there initially announced an efficacy rate of 78 per cent, but revised that down to just over 50 per cent after including mild infections. The Brazil segment of the trial enrolled 12,396. volunteers, and recorded 253 infections, the company said in a statement Friday.

Its stage 3 clinical trials were held in Brazil, Chile, Indonesia and Turkey, with a total of 25,000 volunteers.

UPSC KEY Have you seen our section dedicated to helping USPC aspirants decode daily news in the context of their exams?

📣 Join our Telegram channel (The Indian Express) for the latest news and updates

For all the latest World News, download Indian Express App.

  • Newsguard
  • The Indian Express website has been rated GREEN for its credibility and trustworthiness by Newsguard, a global service that rates news sources for their journalistic standards.
  • Newsguard
0 Comment(s) *
* The moderation of comments is automated and not cleared manually by indianexpress.com.
Advertisement
Advertisement
Advertisement
Advertisement